A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Phase 3 Completed NCT03896581

Condition	Psoriatic Arthritis
Phase	Phase 3
Sponsor	UCB Biopharma SRL
Status	Completed
Enrollment	400 participants
Interventions	Bimekizumab
Start date	Mar 28, 2019
Completion date	Dec 8, 2021
Results posted	Oct 16, 2024

Summary

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthritis (PsA).

Percentage of Participants With American College of Rheumatology 50 (ACR50) Response

From Baseline to Week 16 · percentage of participants

Placebo	6.8 percentage of participants
Bimekizumab 160mg	43.4 percentage of participants

p-value	<0.001
Odds Ratio (OR)	11.139 (95% CI 5.402–22.969)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab i — UCB Biopharma SRL
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский